Bertilimumab is a first-in-class human monoclonal antibody that targets and lowers eotaxin-1 levels. Eotaxin-1 is a chemokine that attracts eosiniphils to sites of inflamation - thus by blocking eotaxin-1, bertilimumab may reduce eosinophil migration or activation and thus provide a benefit to patients suffering from a variety of immunologic and inflammatory diseases. To date, bertilimumab has been well tolerated, with over 100 subjects having received bertilimumab in clinical trials, and has shown promising signs of activity in patients with moderate-to-severe bullous pemphigoid, a rare skin blistering disease. Read More 

Latest News

PRESS RELEASE February 6, 2018

Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018 | Read more 


PRESS RELEASE January 26, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting | Read more 


PRESS RELEASE January 23, 2018

Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018 | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events